Skip to main content
Erschienen in: Updates in Surgery 2/2021

27.11.2020 | Original Article

Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival

verfasst von: Yueh-Wei Liu, Chee-Chien Yong, Chih-Che Lin, Chih-Chi Wang, Chao-Long Chen, Yu-Fan Cheng, Jing-Houng Wang, Yi-Hao Yen

Erschienen in: Updates in Surgery | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

To determine the optimal cutoff time point of early versus late recurrence relative to post-recurrence survival (PRS) among patients who underwent liver resection (LR) for hepatocellular carcinoma (HCC) in a high-volume liver surgery center in East Asia. This was a retrospective study. Patients who underwent LR for HCC between 2011 and 2018 at Kaohsiung Chang Gung Memorial Hospital were enrolled. The optimal cutoff time point to differentiate early versus late recurrence was evaluated relative to PRS. Among 826 patients, 282 (34.1%) of the patients experienced recurrence, with a median time to recurrence of 12.2 months. 6 months was defined as the optimal cutoff time point based on sensitivity analyses relative to PRS. Ninety (31.9%) of the patients developed early recurrence within 6 months, and 192 patients (68.1%) developed late recurrence beyond 6 months. Early recurrence was associated with worse PRS (median PRS, 13.2 versus 48.9 months, p < 0.001), as well as overall survival (OS) (median OS, 16.2 versus 65.4 months, p < 0.001), than late recurrence. Six months was identified as the cutoff time point to differentiate early versus late recurrence among patients undergoing LR for HCC.
Literatur
1.
Zurück zum Zitat EASL Clinical Practice Guidelines (2018) Management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef EASL Clinical Practice Guidelines (2018) Management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef
2.
Zurück zum Zitat Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed
3.
Zurück zum Zitat Cucchetti A, Piscaglia F, Caturelli E et al (2009) Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 16:413–422CrossRefPubMed Cucchetti A, Piscaglia F, Caturelli E et al (2009) Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 16:413–422CrossRefPubMed
4.
Zurück zum Zitat European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef
5.
Zurück zum Zitat Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207CrossRefPubMed Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207CrossRefPubMed
6.
Zurück zum Zitat Ding X, He M, Chan AWH et al (2019) Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 157:1630-1645.e1636CrossRefPubMed Ding X, He M, Chan AWH et al (2019) Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 157:1630-1645.e1636CrossRefPubMed
7.
Zurück zum Zitat Tabrizian P, Jibara G, Shrager B et al (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955CrossRefPubMed Tabrizian P, Jibara G, Shrager B et al (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955CrossRefPubMed
8.
Zurück zum Zitat Groot VP, Gemenetzis G, Blair AB et al (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154–1162CrossRefPubMed Groot VP, Gemenetzis G, Blair AB et al (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154–1162CrossRefPubMed
10.
Zurück zum Zitat Xing H, Zhang WG, Cescon M et al (2020) Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxf) 22:677–689CrossRef Xing H, Zhang WG, Cescon M et al (2020) Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxf) 22:677–689CrossRef
11.
Zurück zum Zitat American Joint Committee on Cancer (2010) American Joint Committee on Cancer Staging Manual, 7th ed. In: Edge SB, Byrd DR, Compton CC et al (eds). Springer, New York, p 175 American Joint Committee on Cancer (2010) American Joint Committee on Cancer Staging Manual, 7th ed. In: Edge SB, Byrd DR, Compton CC et al (eds). Springer, New York, p 175
12.
Zurück zum Zitat Abou-Alfa GK, Pawlik TM, Shindoh J et al (2017) Liver. In: AJCC cancer staging manual, 8th ed, Amin MB (Ed), AJCC, Chicago, p 287 Abou-Alfa GK, Pawlik TM, Shindoh J et al (2017) Liver. In: AJCC cancer staging manual, 8th ed, Amin MB (Ed), AJCC, Chicago, p 287
13.
Zurück zum Zitat Edmonson H, Steiner P (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRef Edmonson H, Steiner P (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRef
14.
Zurück zum Zitat Everhart JE, Wright EC, Goodman ZD et al (2010) Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 51:585–594CrossRefPubMed Everhart JE, Wright EC, Goodman ZD et al (2010) Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 51:585–594CrossRefPubMed
15.
Zurück zum Zitat Benson AB, Abrams TA, Ben-Josef E et al (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350–391CrossRefPubMedPubMedCentral Benson AB, Abrams TA, Ben-Josef E et al (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350–391CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kokudo N, Hasegawa K, Akahane M et al (2015) Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update 3rd JSH-HCC Guidelines. Hepatol Res 45:2CrossRef Kokudo N, Hasegawa K, Akahane M et al (2015) Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update 3rd JSH-HCC Guidelines. Hepatol Res 45:2CrossRef
17.
Zurück zum Zitat Kudo M, Matsui O, Izumi N et al (2014) Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468CrossRefPubMedPubMedCentral Kudo M, Matsui O, Izumi N et al (2014) Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kudo M, Izumi N, Kokudo N et al (2011) HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339–364CrossRefPubMed Kudo M, Izumi N, Kokudo N et al (2011) HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339–364CrossRefPubMed
19.
Zurück zum Zitat Omata M, Lesmana LA, Tateishi R et al (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4:439–474CrossRefPubMedPubMedCentral Omata M, Lesmana LA, Tateishi R et al (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4:439–474CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMed Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMed
21.
Zurück zum Zitat Meniconi RL, Komatsu S, Perdigao F et al (2015) Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 157:454–462CrossRefPubMed Meniconi RL, Komatsu S, Perdigao F et al (2015) Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 157:454–462CrossRefPubMed
22.
Zurück zum Zitat Shindoh J, Kawamura Y, Kobayashi Y et al (2020) Time-to-interventional failure as a new surrogate measure for survival outcomes after resection of hepatocellular carcinoma. J Gastrointest Surg 24:50–57CrossRefPubMed Shindoh J, Kawamura Y, Kobayashi Y et al (2020) Time-to-interventional failure as a new surrogate measure for survival outcomes after resection of hepatocellular carcinoma. J Gastrointest Surg 24:50–57CrossRefPubMed
23.
Zurück zum Zitat Van Deusen MA, Abdalla EK, Vauthey JN et al (2005) Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 5:377–383CrossRefPubMed Van Deusen MA, Abdalla EK, Vauthey JN et al (2005) Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 5:377–383CrossRefPubMed
24.
Zurück zum Zitat Torzilli G, Donadon M, Belghiti J et al (2016) Predicting individual survival after hepatectomy for hepatocellular carcinoma: a novel nomogram from the “HCC East & West Study Group.” J Gastrointest Surg 20:1154–1162CrossRefPubMed Torzilli G, Donadon M, Belghiti J et al (2016) Predicting individual survival after hepatectomy for hepatocellular carcinoma: a novel nomogram from the “HCC East & West Study Group.” J Gastrointest Surg 20:1154–1162CrossRefPubMed
25.
Zurück zum Zitat Galle PR, Foerster F, Kudo M et al (2019) Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 2019(39):2214–2229CrossRef Galle PR, Foerster F, Kudo M et al (2019) Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 2019(39):2214–2229CrossRef
26.
Zurück zum Zitat Poon RT (2009) Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16:792–794CrossRefPubMed Poon RT (2009) Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16:792–794CrossRefPubMed
27.
Zurück zum Zitat Yamamoto Y, Ikoma H, Morimura R et al (2015) Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol 21:1207–1215CrossRefPubMedPubMedCentral Yamamoto Y, Ikoma H, Morimura R et al (2015) Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol 21:1207–1215CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Toyoda H, Lai PB, O’Beirne J et al (2016) Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer 114:744–750CrossRefPubMedPubMedCentral Toyoda H, Lai PB, O’Beirne J et al (2016) Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer 114:744–750CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558CrossRefPubMed Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558CrossRefPubMed
30.
Zurück zum Zitat Chan AWH, Zhong J, Berhane S et al (2018) Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 69:1284–1293CrossRefPubMed Chan AWH, Zhong J, Berhane S et al (2018) Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 69:1284–1293CrossRefPubMed
31.
Zurück zum Zitat Lee YC, Cohet C, Yang YC, Stayner L et al (2009) Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 38:1497–1511CrossRefPubMed Lee YC, Cohet C, Yang YC, Stayner L et al (2009) Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 38:1497–1511CrossRefPubMed
32.
Zurück zum Zitat Shen YC, Hsu C, Chen LT et al (2010) Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. J Hepatol 52:889–894CrossRefPubMed Shen YC, Hsu C, Chen LT et al (2010) Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. J Hepatol 52:889–894CrossRefPubMed
33.
Zurück zum Zitat Wong JS, Wong GL, Tsoi KK et al (2011) Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 33:1104–1112CrossRefPubMed Wong JS, Wong GL, Tsoi KK et al (2011) Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 33:1104–1112CrossRefPubMed
34.
Zurück zum Zitat Poon RT, Fan ST, Lo CM et al (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function. Ann Surg 235:373–382CrossRefPubMedPubMedCentral Poon RT, Fan ST, Lo CM et al (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function. Ann Surg 235:373–382CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Sandri GBL, Ettorre GM, Aldrighetti L et al (2019) Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Surg Endosc 33:1451–1458CrossRef Sandri GBL, Ettorre GM, Aldrighetti L et al (2019) Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Surg Endosc 33:1451–1458CrossRef
36.
Zurück zum Zitat Levi GB, Sandri QL, Ravaioli M et al (2020) The role of salvage transplantation in patients initially treated with open versus minimally invasive liver surgery: an intention-to-treat analysis. Liver Transpl 26:878–887CrossRef Levi GB, Sandri QL, Ravaioli M et al (2020) The role of salvage transplantation in patients initially treated with open versus minimally invasive liver surgery: an intention-to-treat analysis. Liver Transpl 26:878–887CrossRef
Metadaten
Titel
Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival
verfasst von
Yueh-Wei Liu
Chee-Chien Yong
Chih-Che Lin
Chih-Chi Wang
Chao-Long Chen
Yu-Fan Cheng
Jing-Houng Wang
Yi-Hao Yen
Publikationsdatum
27.11.2020
Verlag
Springer International Publishing
Erschienen in
Updates in Surgery / Ausgabe 2/2021
Print ISSN: 2038-131X
Elektronische ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-020-00931-2

Weitere Artikel der Ausgabe 2/2021

Updates in Surgery 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.